Halozyme Therapeutics

Type: Public
On the web: http://www.halozyme.com
Employees: 129
Employee growth: 40.2%

Halozyme Therapeutics makes enzymes for therapeutic and drug delivery applications. The company's products are based on recombinant human PH20, a human synthetic enzyme it hopes will offer safety benefits over animal-derived versions. The firm's first commercial product, Cumulase, is used for in-vitro fertilization. Another product, Hylenex, is used as an adjuvant for drug and fluid infusions. Products under development include drug delivery agents using the company's Enhanze technology, as well as therapeutic enzymes for cancer, metabolism, and dermatology applications. Halozyme's development partners include Roche and Baxter International.

Key numbers for fiscal year ending December, 2008:
Sales: $8.8M
One year growth: 130.7%
Net income: ($48.7)M

Officers:
Chairman: Kenneth J. (Ken) Kelley
VP Manufacturing and Operations: William J. Fallon
VP and CFO: Kurt A. Gustafson

Competitors:
Cook Group
CooperSurgical
Irvine Scientific

This article does not cite any references or sources. Please help improve this article by adding citations to reliable sources. Unsourced material may be challenged and removed. (September 2008)

Halozyme Therapeutics

company_type = Public (NASDAQ: HALO)
Founded	1998
Headquarters	San Diego, California, USA
Key people	Jonathan E. Lim, President & CEO
Industry	Biopharmaceutical
Products	Biologics
Revenue	▲$ 3,799,521 USD (2007)
Employees	130
Website	www.halozyme.com

Halozyme Therapeutics, based in San Diego, California, is a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the endocrinology, oncology, dermatology and drug delivery markets.

• http://www.halozyme.com

This entry is from Wikipedia, the leading user-contributed encyclopedia. It may not have been reviewed by professional editors (see full disclaimer)